Login to Your Account



Biolinerx shares hop on dual-action data in phase II AML trial

By Jennifer Boggs
Staff Writer

Monday, December 16, 2013

Though still very early stage, initial Phase II results testing Biolinerx Ltd.’s CXCR4 antagonist, BL-8040, in relapsed and refractory acute myeloid leukemia (AML) patients caught the attention of Wall Street Monday, sending shares of the Jerusalem-based firm jumping 15 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription